GleamWall
中文EN

TCRX TScan Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1783328 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-38.4%
TTM net income YoY19.3%
TTM EPS YoY20.5%
Revenue 3-yr CAGR-32.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,246.8%
Net margin-2,219.2%
FCF margin-2,153.3%
EBITDA margin-2,192.3%

Returns

ROE-126.4%
ROA-57.0%
ROIC (approx.)-3,777.3%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets73.1%
Debt / equity0.87x
Current ratio2.03x
Interest coverage-40.67x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue14.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$10.32M$2.82M
R&D expense$114.15M$107.35M
SG&A expense$31.99M$30.29M
Operating income-$135.81M-$134.82M
Interest expense$2.77M$3.65M
Income tax$0—
Net income-$129.77M-$127.50M
EBITDA-$132.91M-$130.72M
EPS (basic)-1.00-1.14
EPS (diluted)-1.00-1.14
Weighted avg. shares (diluted)129.78M111.99M
Balance sheet
Cash & equivalents$152.41M$183.72M
Short-term investments—$111.42M
Current assets$157.21M$292.72M
PP&E, net$8.71M$7.24M
Total assets$228.79M$371.12M
Current liabilities$18.70M$35.96M
Long-term debt$32.53M$32.07M
Total debt$32.53M$32.07M
Total liabilities$105.67M$130.15M
Shareholders' equity$123.12M$240.97M
Net debt-$119.87M-$151.65M
Cash flow statement
Operating cash flow-$135.32M-$110.82M
Capital expenditure$4.41M$3.83M
Free cash flow-$139.73M-$114.65M
Investing cash flow$109.37M-$52.61M
Financing cash flow-$336,000$208.76M
Depreciation & amortization$2.90M$4.10M
Stock-based compensation$11.71M$9.55M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.